XDWH:LSE:LSE-Xtrackers MSCI World Health Care UCITS ETF 1C (USD)

ETF | Others |

Last Closing

USD 54.79

Change

-0.18 (-0.33)%

Market Cap

N/A

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

+1.61 (+0.59%)

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

+2.00 (+1.02%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+0.33 (+0.24%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.05 (+0.38%)

USD 584.80B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.14 (+0.80%)

USD 583.82B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+0.25 (+0.39%)

USD 266.08B
0QZO:LSE 0QZO

+1.15 (+1.21%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

+0.19 (+0.65%)

USD 204.07B
0QZ3:LSE Qualcomm Inc.

N/A

USD 202.26B

ETFs Containing XDWH:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.34% 56% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.34% 56% F 58% F
Trailing 12 Months  
Capital Gain 16.13% 57% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.13% 57% F 58% F
Trailing 5 Years  
Capital Gain 56.50% 73% C 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.50% 73% C 74% C
Average Annual (5 Year Horizon)  
Capital Gain 9.40% 63% D 66% D+
Dividend Return 9.40% 62% D 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.13% 66% D+ 80% B-
Risk Adjusted Return 92.77% 89% A- 94% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike